Mode
Home
Research
Clinical Trials Drug Pipeline Weekly Digests
Reference
Conditions Medications
Community
Questions
Text Size
Log in / Sign up
Home › Medications › Prevenar 13

Prevenar 13

0 published articles · Updated continuously

Clinical Trial Landscape

Clinical Trials of Prevenar 13

17 trials tracked of Prevenar 13: 11 in phase 3 or 4 and 3 with published results. The most-cited published study has 26 citations.

17Trials tracked
11Phase 3 & 4
0Recruiting
3With published results
Phase distribution
Phase 4 1 Phase 3 10 Phase 2 5 Other / NA 1
  1. Phase 3 Safety, Tolerability, and Immunogenicity of V114 in Healthy Infants (V114-025) Completed · 26 cited
  2. Phase 3 Safety, Tolerability, and Immunogenicity of a 3-dose Regimen of V114 in Healthy Infants (PNEU-PED-EU-2/V114-026) Completed · 21 cited
  3. Phase 3 Study of 10-valent Pneumococcal Conjugate Vaccine (Pneumosil) Administered in a 2+1 Schedule to Healthy Infants Completed · 13 cited
  4. Phase 4 Clinical and Immunological Efficiency of Bacterial Vaccines at Adult Patients With Bronchopulmonary Pathology Completed
  5. Phase 3 Spanish Mixed HEXA/PENTA/HEXA Schedule (V419-010) Completed
  6. Phase 3 An Efficacy Study of GlaxoSmithKline (GSK) Biologicals' Candidate Influenza Vaccine GSK2321138A in Children Completed
Show 11 more trials
  1. Phase 3 Safety, Tolerability, and Immunogenicity of V419 in Healthy Infants When Given at 2, 4, and 11 to 12 Months (V419-008) Completed
  2. Phase 3 Immunogenicity and Safety Study of 1 and 2 Doses of GlaxoSmithKline (GSK) Biologicals' Meningococcal Vaccine MenACWY-TT (GSK134612) in Toddlers, Persistence up to 5 Years After Vaccination and Co-administration With Pfizer's Prevenar 13™Vaccine Completed
  3. Phase 3 This Study Will Evaluate the Immunogenicity, Reactogenicity and Safety of the Routine Infant Vaccines Pediarix®, Hiberix® and Prevenar 13® When Co-administered With GlaxoSmithKline (GSK) Biologicals' Liquid Human Rotavirus Vaccine (HRV) as Compared to GSK's Licensed Lyophilized Vaccine Completed
  4. Phase 3 Safety, Tolerability, and Immunogenicity of V419 in Healthy Infants When Given at 2, 3, 4 and 12 Months (V419-007) Completed
  5. Phase 3 Primary Vaccination With Either Synflorix™ or Prevenar 13™ or Both Vaccines and Booster Vaccination With Synflorix™ Completed
  6. Phase 2 Safety and Immunogenicity of New Formulations of GlaxoSmithKline Biologicals' DTPa-HBV-IPV/Hib Vaccine (GSK217744) Completed
  7. Phase 2 Safety and Immunogenicity of a Booster Dose of New Formulations of GlaxoSmithKline Biologicals' DTPa-HBV-IPV/Hib Vaccine (GSK217744) Completed
  8. Phase 2 Safety and Immunogenicity of a 10 Valent Pneumococcal Conjugate Vaccine (SIILPCV10) in Healthy Adults, Toddlers, Infants Completed
  9. Phase 2 Study of GlaxoSmithKline Biologicals' GSK2202083A Vaccine in Healthy Infants Completed
  10. Phase 2 Safety & Immunogenicity of Pneumococcal Vaccine 2189242A Co-administered With DTPa-HBV-IPV/Hib in Healthy Infants Completed
  11. N/A Safety Surveillance of Pneumococcal 13-valent Conjugate Vaccine Among Filipinos Completed

Showing the 17 most-cited and recently-updated of 17 trials. Browse the full registry →

Trial data sourced from ClinicalTrials.gov. Counts describe the research landscape and are not a treatment recommendation. Informational only — not medical advice.

HCP Mode — summaries include clinical detail, trial data, and statistical outcomes.
Patient Mode — summaries use plain language, avoiding clinical jargon.
No published articles yet for this medication. Check back soon.